Personal CGM (Init)

What is the scientific evidence?

2006 Guard Control CGM Study

Study Design

  • 3 month study
  • 81 children and 81 adults
  • On intensive insulin therapy
  • type 1 (A1C > 8.1%)
  • 8 European centers
  • 7 Countries
Outcome
Personal CGM improved the outcomes of patients using intensive insulin therapy

Guardian CGM
  • 50% of the subjects achieved an A1C reduction of ≥ 1.0%
  • 26% of the subjects achieved a reduction of ≥ 2.0%
  • No increase in hypoglycemia

Deiss, D, et. al. Improved glycemic control in poorly controlled patients with Type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;23(12):2730-2732.
 

What is the scientific evidence?

Higher utilization of Personal CGM is associated with better outcomes

Study Design

  • 6 Month Study:
  • 322 Type 1
  • 114 children (8-14 years)
  • 110 adolescents (15-24 years)
  • 98 adults (≥ 25 years)
  • On intensive insulin therapy
  • Type 1 (A1C 7.0%-10.0%)
Outcome

  • Change in A1C levels at 26 weeks
Personal CGM BG Meter

The Juvenile Diabetes Research Foundation published in The New England Journal of Medicine in 2008:359:1464-1476.
 

What is the scientific evidence?

Average A1C reduction for patients wearing CGM 6 days/week: 0.5%

Percentage of patients who used sensors at least 6 days per week on average over 26 weeks
Absolute Reduction in A1C (%) from baseline for all patients in each age cohort
Higher utilization of Personal CGM is associated with better outcomes

The reported results were for the entire population of each age group segmentation. The higher percentage of patients in each age group who used sensors at least 6 days per week over the 26 weeks, the higher the absolute reduction in A1C for all patients in each age group.

The Juvenile Diabetes Research Foundation published in The New England Journal of Medicine in 2008:359:1464-1476
 

What is the scientific evidence?

Can Personal CGM reduce A1C for patients using intensive insulin therapy?

Yes, frequent use of Personal CGM can reduce A1C by 0.5%-0.6% without increasing hypoglycemia when used with intensive insulin therapy.1

1The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The New Engl J Med. 2008;359:1464-1476